Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Queensland Health
Johnson and Johnson
Citi
UBS
McKesson
Federal Trade Commission
Chinese Patent Office
Moodys

Generated: August 21, 2018

DrugPatentWatch Database Preview

TAGRISSO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Tagrisso patents expire, and what generic alternatives are available?

Tagrisso is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-one patent family members in thirty-eight countries.

The generic ingredient in TAGRISSO is osimertinib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the osimertinib mesylate profile page.

Summary for TAGRISSO
Drug patent expirations by year for TAGRISSO
Generic Entry Opportunity Date for TAGRISSO
Generic Entry Date for TAGRISSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for TAGRISSO
1421373-65-0
1610419-47-0
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-
3C06JJ0Z2O
4CA-0243
ABP001123
AK170511
AKOS025290756
AOB6268
AS-16943
AZD 9291
AZD-9291
AZD9291
BDBM50029668
C28H33N7O2
CHEBI:90943
CHEMBL3353410
CS-2018
D0RT2C
DB09330
DUYJMQONPNNFPI-UHFFFAOYSA-N
EX-A314
FT-0696828
GTPL7719
HMS3653E10
HY-15772
KB-330516
KS-000007ZW
Mereletinib
mereletinib (obsolete INN)
Mereletinib [INN]
Mereletinib pound AZD-9291 Osimertinib pound(c)
MFCD27988062
MolPort-035-395-886
N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
osimertinib
Osimertinib [USAN]
osimertinib mesilate
QC-11454
s7297
SC-94470
SCHEMBL14660911
Tube720
UNII-3C06JJ0Z2O
X3507
ZINC98023177

US Patents and Regulatory Information for TAGRISSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

International Patents for TAGRISSO

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
UBS
Cerilliant
Cipla
Express Scripts
AstraZeneca
McKinsey
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.